Low-dose chemotherapy Empowers alpha-Particle Radionuclide Therapy Against Metastatic Breast Cancer
Wednesday, July 16, 2025
3:16 PM - 3:27 PM EDT
Location: 119 A
Introduction: Advanced triple negative breast cancer (TNBC) remains incurable. This is due to the development of tumor resistance and/or the location of the metastatic tumors that make it difficult to treat aggressively without adverse side effects, rendering prognosis extremely poor. The efficacy of systemically injected alpha-particle dendrimer-radioconjugates to inhibit tumor growth and prolong survival, in the presence and absence of low-dose standard-of-care chemotherapy, was evaluated on immune competent mice with syngeneic TNBC implanted in the brain, the mammary fat pad and/or subcutaneously.
Learning Objectives:
At the completion of this activity, participants will know
Demonstrate nanoparticle-based approaches for enhancing delivery and efficacy.
Learn the principles of radionuclide therapy and its enhancement when combined with chemotherapy.
Describe about strategies to minimize off-target toxicities while maximizing tumor-specific effects.
Rajiv Nair – Ph.D., Chemical and Biomolecular Engineering, Institute for NanoBioTechnology, Johns Hopkins University; Aira Sarkar – Ph.D. Candidate, Chemical and Biomolecular Engineering, Institute for NanoBioTechnology, Johns Hopkins University; Daniele Gilkes – Assistant Professor, Chemical and Biomolecular Engineering, Institute for NanoBioTechnology, Department of Oncology, Johns Hopkins University; Rangaramanujam Kannan – Professor, Center for Nanomedicine at the Wilmer Eye Institute, Department of Ophthalmology, Johns Hopkins University; Stavroula Sofou – Professor, Chemical and Biomolecular Engineering, Institute for NanoBioTechnology, Sidney Kimmel Comprehensive Cancer Center, Cancer Invasion & Metastasis Program, Department of Oncology, Johns Hopkins University
